Dr. Anderson's research interests are in HIV stem cell gene therapy, and focus on translating key research findings into clinical applications for the treatment of infected individuals.
Dr. Anderson’s research interests include Hematopoietic stem cell gene therapy for the treatment of various diseases including HIV, lysosomal storage diseases, and neurological diseases. His research efforts focus on developing therapies for these diseases and moving them toward human clinical trials.
Hematology and Oncology
M.A.S., University of California Davis, Sacramento CA 2018
Ph.D., Colorado State University, Fort Collins, Colorado, 2005
B.S., University of Wisconsin, La Crosse WI 2000
American Society of Gene and Cellular Therapy
Honors and Awards
Acceptance into the UC Davis Mentored Clinical Research Training Program., 2013
UC Davis Academic Federation Travel Award 2011, 2012, 2013
UC Davis Academic Federation Innovative Development Award, 2012
First place award for poster at "Medical Student Research and Poster Forum" at UC-Davis Medical Center, Symposium, 2009
American Society of Hematology Travel Award for abstract poster presentation at ASH conference, 2008
Select Recent Publications
Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmai J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolta J, Anderson JD, Anderson JS. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis and Potentiate Growth Factor Secretion. Stem Cell Dev. 2019;28(6):398-409.
Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, AndersonJD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. Cell Transplant. 2016;4(25):677-86.
Konadu KA, Anderson JS, Huang M-B, Ali SA, Powell MD, Villinger F, and Bond VC. Hallmarks of HIV-1 pathogenesis are modulated by Nef’s Secretion Modification Region. Journal of AIDS and Clinical Research. 2015;6(7):476.
Anderson JS and Bauer G. Stem Cell Transplantation in the context of HIV: How Can We Cure HIV Infection? Expert Reviews in Clinical Immunology. 2014;10(1):107-116.
Gericota B, Anderson JS, Mitchell G, Borjesson DL, Sturges BK, Nolta JA, and Sieber-Blum M. Canine epidermal neural crest stem cells: characterization and potential as therapy candidate for a large animal model of spinal cord injury. Stem Cells Translational Medicine. 2014;(3):334-345.
Yang Y, Zhang S, Fong R, Barraza A, Nolta JA, Torbett BE, Abedi M, Bauer G, and Anderson JS. Safety and efficacy of a tCD25 Preselective Combination Anti-HIV Lentiviral Vector in Human Hematopoietic Stem and Progenitor Cells. Stem Cells. 2014;33(3): 870-879.
Kalomoiris S, Lawson J, Chen RX, Bauer G, Nolta JA, and Anderson JS. CD25 preselective anti-HIV vectors for improved HIV gene therapy. Human Gene Therapy Methods, 2012;23: 366-375.
Anderson JS and Bauer G. Fighting HIV with stem cell therapy: one step closer to human trials? Expert Review of Anti-Infective Therapy, 2012;10: 1071-1073.
Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, and Anderson JS. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. Journal of Virology, 2012;86: 5719-5729.
Anderson JS. Using TRIM5alpha as an HIV therapeutic: the alpha gene? Expert Opinion on Biological Therapy, 2013;13: 1029-1038.